Kristin Richeimer
Heather Wakelee, MD
Welcome Letter
Dear Colleagues and Friends, Welcome to the 2021 IASLC Annual Report! As we look back on 2021, we see how our lives, our Association and the lung cancer community as a whole continued to be impacted by the pandemic. While we hoped that 2021 would bring us back together to meet in person, that was not to be. However, IASLC was able to produce extraordinary publications and education offerings within a virtual platform.
IASLC Year in Review
Dr. Heather Wakelee welcomes you to the IASLC 2021 Annual Report.
IASLC's International and Multidisciplinary Membership
Despite the worldwide focus on COVID-19, IASLC members from all corners of the world continued to drive scientific advancements and collaboration. IASLC members worked in incredibly difficult circumstances during the pandemic. Furthering the mission of the IASLC, members were supported in these global efforts by receiving discounted registration fees to meetings and educational events, complimentary access to the Journal of Thoracic Oncology and discounted publication fees for the open-access IASLC Journal, JTO Clinical and Research Reports. (JTO CRR)
Members By Country/Region
Members by Primary Specialty
| Labels | Values |
|---|---|
| Medical Oncology | 1984 |
| Thoracic Surgery | 862 |
| Other/Unknown | 613 |
| Pulmonary Medicine | 593 |
| Cancer Research | 412 |
| Radiation Oncology | 389 |
| Pathology | 335 |
| Advocacy | 270 |
| Biotech/Pharmaceutical | 170 |
| Nursing | 93 |
| Diagnostic Radiology | 90 |
| Pharmacy | 51 |
| Biostatistics | 40 |
| Smoking Cessation | 11 |
| Hemotology | 8 |
| Resp Therapy/Physiotherapy | 6 |
donut
Professional Activity/Practice
| Labels | Values |
|---|---|
| Academic Medical Center | 2966 |
| Other/Unknown | 830 |
| Cancer Center | 655 |
| Pharmaceutical/Biotech | 554 |
| Private Practice (Hospital) | 216 |
| Private Practice (Office) | 202 |
| Training Program | 147 |
| Non-Profit or Advocacy | 115 |
| Laboratory Research | 101 |
| Government Agency | 83 |
| Administration | 33 |
| Retired | 25 |
donut
Committees
Serving on an IASLC committee in a volunteer capacity, members contribute their specialized skills and talents to help define the work of the organization, develop educational content, shape the association's messaging, plan annual meetings, contribute to publications authored by the IASLC, and more.
Committee Chair:
Fiona McDonald
The advanced radiation technology (ART) committee focuses on educating members about emerging techniques, technologies and strategies for treating thoracic malignancies.
Committee Chair:
Brendon Stiles
The Communications Committee develops campaigns to increase IASLC brand recognition and credibility while educating the public about complex lung and thoracic cancer issues. The committee also reviews articles for publication in the Journal of Thoracic Oncology and determines which pieces to promote to the media.
Committee Chair:
Christian Rolfo
The Education Committee plans and implements educational activities in accordance with IASLC’s mission of providing education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public.
Committee Chair:
Paul Baas
Mesothelioma is a rare tumor with limited options that has seen several research updates in 2020, many of which were spearheaded by members of this committee.
Committee Chair:
Wendy Cooper
For more than 35 years, the IASLC Pathology Committee has played a fundamental role in fulfilling core aspects of the association's mission.
Committee Chair:
Stephen Lam
The Screening and Early Detection Committee provides leadership and oversight of IASLC activities in these areas. The committee works with appropriate internal committees to enhance the quality and quantity of IASLC cancer prevention initiatives and provides leadership in partnership with other societies in the area of cancer prevention and screening.
Committee Chair:
Bill Evans
Improving patient care by raising awareness of cessation-related data and by provision of information regarding the latest and most successful cessation techniques for patients with lung cancer.
Committee Chair:
Ahmed Rabea
The Career Development and Fellowship Committee focuses on supporting the next generation of lung cancer specialists.
Committee Chair:
Apar Kishor Ganti
Committee Co-chair:
Nick Pavlakis
The Continuing Medical Education (CME) Committee oversees the educational program of IASLC to ensure that activities are planned and implemented in compliance with all ACCME Accreditation Requirements, including the ACCME Standards for Commercial Support℠. The CME Committee is also responsible for ensuring that IASLC’s CME activities meet the requirements of the American Medical Association Physician’s Recognition Award (AMA PRA).
Committee Chair:
Nan Wu
The Membership Committee review and recommend membership status requirements and benefits for all IASLC members. Members of this committee also strategize and implement tactics to increase and retain association membership in their area of specialty and region.
Committee Chair:
Maria Ftanou
The Nursing & Allied Health Professionals Committee (NAHP) within IASLC is comprised of multidisciplinary clinicians and researchers each with a unique perspective, committed to advancing the education of both practitioners and patients in thoracic oncology. Our goal is to improve and optimize outcomes for oncology patients and families across the cancer trajectory through diagnosis, treatment, survivorship and end of life.
Committee Chair:
Jill Feldman
The Patient Advocates Committee ensures that the IASLC addresses the informational needs of the public, advocates and patients living with lung and thoracic cancers. This committee also comprehensively addresses the educational and related needs of the public as an important constituency in the work of the association.
Committee Chair:
Hisao Asamura
Staging lung cancer and other thoracic malignancies accurately is critical in deciding treatment regimens and ensures best standardized care for patients worldwide. The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, as well as for thymic and esophageal cancers and mesothelioma.
IASLC 2021 World Conference on Lung Cancer
The IASLC made an early decision to execute the 2021 World Conference on Lung Cancer (WCLC 2021) as a fully virtual event. The WCLC Conference Chairs, Drs. David Harpole, Thomas Stinchcombe, and Kristin Higgins continued the IASLC’s tradition of delivering high-quality educational programs marked by practice-changing abstracts.
WCLC 2021 Quick Facts
Media Coverage
Journal of Thoracic Oncology
The Journal of Thoracic Oncology's (JTO) influence on the field is represented by its increased impact factor, which has climbed dramatically in recent years. The 2020 impact factor for JTO is 15.609 up from 13.357 in 2019. This moves the journal’s rank to 4th among 64 respiratory medicine journals and 13th among 242 oncology journals.
JTO Clinical and Research Reports
JTO Clinical and Research Reports (JTO CRR) transitioned to article-based publishing and became a monthly publication in 2021. In 2021, JTO CRR articles became indexed and available through PubMed Central.
JTO Impact Factor on the Rise
| Labels | Values |
|---|---|
| 2008 | 3.508 |
| 2009 | 4.547 |
| 2010 | 4.040 |
| 2011 | 3.661 |
| 2012 | 4.473 |
| 2013 | 5.8 |
| 2014 | 5.282 |
| 2015 | 5.040 |
| 2016 | 6.595 |
| 2017 | 10.336 |
| 2018 | 12.460 |
| 2019 | 13.357 |
| 2020 | 15.609 |
bar
It is generally difficult for organ-specific oncology journals to make a significant impact in the oncology publishing landscape. With an Impact Factor of 15.609, JTO is the leading journal in thoracic oncology and, in the top fifteen (ranked 14th) of all cancer journals,” said Editor-in-Chief, Dr. Alex A. Adjei, MD, Ph.D. “JTO’s emphasis on multidisciplinary research is one of its strengths and serves the broad community of researchers in this field.
Patient Advocacy
The IASLC recognizes the importance and value that patients with lung cancer, their caregivers, and patient advocates bring to the lung cancer community and to the organization.
2021 Cancer Care Team Awards
The 2021 IASLC Cancer Care Team Award recognizes extraordinary patient care in the field of thoracic malignancies. Awardees are nominated by patients and their loved ones.
Financials
| December 31 (Unaudited) | ||
|---|---|---|
| 2021 | 2020 | |
| Program Revenues | $12,78,644 | $7,148,662 |
| Membership Revenues | $744,497 | $632,870 |
| Other Revenues | $927,858 | -- |
| Total Revenues | $14,465,999 | $7,781,532 |
| Direct Program Expenses | $7,582,308 | $4,584,120 |
| G&A Expenses | $5,115,252 | $5,520,532 |
| Total Expenses | $12,697,560 | $10,104,652 |
| Operating Surplus(Deficit) | $1,759,439 | ($2,323,120) |
| Other Income/Expense | $950,000 | $65,296 |
Revenue by Type
| Labels | Values |
|---|---|
| Conferences & Meetings | 62% |
| Scientific Projects | 9% |
| Publications | 12% |
| Membership | 5% |
| Fellowships | 5% |
| Federal Grants | 6% |
donut
International Lung Cancer Foundation
Donation Sources
| Labels | Values |
|---|---|
| membership Renewals | 5% |
| Online Donations | 14% |
| Honoraria | 6% |
| Meetings (not WCLC) | 6% |
| WCLC | 21% |
| Adi Gazdar Estate | 48% |
donut